Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Romiplostim plus dexamethasone vs dexamethasone in newly diagnosed primary immune thrombocytopenia
2024-514147-28-00Phase 3Authorised
- Sponsor
- Fundación Pública Andaluza para la Gestión de la Investigación
- Start
- Jul 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 3
01
Overview
Phase 3, randomised, open-label trial in immune thrombocytopenia (ITP) comparing Romiplostim plus dexamethasone with Dexamethasone (2 arms). Primary endpoint: 6mSROT-50 at 6 months from treatment cessation. Planned start Jul 2024; status: authorised.
02
Drugs
romiplostimdexamethasone
03
Conditions
immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on 2024-514147-28-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514147-28-00.